A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer (NCT07225946)
A Phase 3 Randomized, Open-label Study of Pasritamig (JNJ-78278343), a T-cell-engaging Agent Targeting Human Kallikrein 2, With Docetaxel Versus Docetaxel for Metastatic Castration-resistant Prostate Cancer
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to find out whether treatment with pasritamig and docetaxel prolongs radiographic progression free survival (rPFS) (the length of time from start of treatment until disease worsens as determined by scans or death due to any cause) when compared to treatment with docetaxel in participants with metastatic castrate-resistant prostate cancer (mCRPC; a cancer of prostate, a male reproductive gland found below the bladder, that grows despite low levels of male hormones).
Who can join: Review the eligibility criteria below.
Location: Arizona Clinical Trials — Chandler, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (152 Sites)
Showing the first 25 of 152 sites.
- Arizona Clinical Trials — Chandler, Arizona
- Arkansas Urology — Little Rock, Arkansas
- MemorialCare Orange Coast Medical Center — Fountain Valley, California
- University Of California San Diego — La Jolla, California
- Cancer and Blood Specialty Clinic — Los Alamitos, California
- USC Norris Comprehensive Cancer Center — Los Angeles, California
- Valkyrie Clinical Trials — Los Angeles, California
- Kaiser Permanente Southern California — Riverside, California
- Sharp Center for Research — San Diego, California
- Providence Saint John s Health Center — Santa Monica, California
- Rocky Mountain Cancer Centers — Aurora, Colorado
- Vail Health Shaw Cancer Center — Edwards, Colorado
- Grand Valley Oncology — Grand Junction, Colorado
- Colorado Clinical Research — Lakewood, Colorado
- AdventHealth Orlando — Orlando, Florida
- Florida Cancer Specialists — Sarasota, Florida
- Winship Cancer Institute Emory University — Atlanta, Georgia
- Duly Health and Care — Lisle, Illinois
- Cancer Center of Kansas Heritage Plaza Medical Building — Wichita, Kansas
- St Elizabeth Healthcare — Edgewood, Kentucky
- Norton Cancer Institute — Louisville, Kentucky
- East Jefferson General Hospital — Metairie, Louisiana
- University of Maryland — Baltimore, Maryland
- Johns Hopkins Hospital — Baltimore, Maryland
- Johns Hopkins Medical Institutions — Baltimore, Maryland
📞 Contact the Study Coordinator
Phone: (844) 434-4210
Email: Participate-In-This-Study1@its.jnj.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Prostatic Neoplasms, Castration-Resistant
- A Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer — Tucson, Arizona
- A Study of Real-World Characteristics, Treatment Patterns, and Outcomes Among mCRPC Patients Previously Treated With an Androgen Receptor Pathway Inhibitor, Taxane-Based Chemotherapy, and Lutetium-177 Vipivotide Tetraxetan — East Hanover, New Jersey
- 64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE) — Stanford, California
- Study of TVB-2640 in Men With Metastatic Castration-Resistant Prostate Cancer — New York, New York
- A Study of Real-World Characteristics, Treatment Patterns, and Clinical Outcomes in Patients With Metastatic Castration-Resistant Prostate Cancer — East Hanover, New Jersey
Explore by condition: All Prostatic Neoplasms, Castration-Resistant clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.